420 with CNW – Medical Marijuana Allows ADHD Patients to Take Fewer Prescription Drugs

February 21, 2020 04:20:31

A new study has found that people with ADHD (attention-deficit hyperactivity disorder) tend to use less prescription drugs, which are powerful, addictive, and psychostimulants when they consume more medical marijuana.

The researchers found that patients who consumed medical marijuana compounds, such as cannabinoids and terpenes, reported a higher occurrence of stopping usage of all ADHD medication. The study findings were published in the Rambam Maimonides Medical Journal last month.

The researchers said that in the study, they demonstrated how ADHD patients treated using medical marijuana stopped using their prescription medication, especially those who consumed medical marijuana in high doses.

The best results were realized when patients used the cannabinoid CBN (cannabinol), which is found in a small amount in select marijuana plants. The researchers further stated that more research is required to fully understand if marijuana and its compounds can be used for treating ADHD.

The researchers also concluded that although the results are not causal, they may shed light on the potential benefits of medical marijuana on ADHD symptoms. And this could motivate scientists to investigate further to endorse the study results. And maybe, cannabis could be approved as a treatment for ADHD in states where marijuana is legal.

The study respondents consisted of 53 medical marijuana patients from Isreal who were in the database of people who had previously agreed to participate in the study. The patients were also diagnosed with ADHD. Out of the 53 patients, 37 of them were suffering from a mental health condition in addition to ADHD.

The study respondents were asked to report monthly on an individual basis of the method of marijuana consumption, the manufacturer, and marijuana strain name between the month of October 2019 and January 2020.

They found that higher doses of marijuana compounds (Phyto-cannabinoids and terpenes) helped the patients reduce the ADHD prescription drugs they used.

The researchers further wrote that previous studies on ADHD and marijuana ignored the inherent complexities and variability between marijuana strains and a combination of cultivars; instead, they viewed marijuana as a single product.

Most of the ADHD patients in the study obtained medical marijuana cards for chronic pain or cancer treatment instead of neurological disorders.

The study, which was funded by the Evelyn Gruss Lipper Charitable Foundation, found that 47 patients consumed marijuana through smoking or vaporization.

The study divided the consumers into high and low doses. There were 27 different combinations of marijuana strains, and apart from CBN, THC, THCV, and CBD were also found to reduce the consumption of prescription medications among ADHD patients.

Industry watchers say that cannabis companies like ChineseInvestors.com Inc. (OTCQB: CIIX) expect even more studies to prove many of the other health benefits that have been linked to cannabis.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

Denver, Colorado
303.498.7722 Office

CNW420 is part of the InvestorBrandNetwork.